Somalia ranks among the 30 countries with the highest multidrug-resistant tuberculosis (MDR-TB) burden globally. Tuberculosis (TB) patients in Somalia often face numerous barriers to accessing timely diagnosis and appropriate treatment, which significantly contributes to worse health outcomes and the development of drug-resistant tuberculosis (DR-TB). A new, shorter treatment regimen for DR-TB is changing patients' lives and providing a new hopeful outlook for tuberculosis treatment in Somalia.
“The BPaLM treatment regimen, which gets its name from being composed of the drugs bedaquiline, pretomanid, linezolid, and moxifloxacin, has reduced both the duration of treatment and the number of tablets a patient has to take,” says Dr. Ahmed Hassan, a medical doctor who has worked for 18 years at the Mudug Tuberculosis Hospital in Galkayo, which is supported by Doctors Without Borders/Médecins Sans Frontières(MSF). “Now, treatment lasts only six months, and patients take just six or seven tablets daily. This has greatly improved treatment compliance and reduced many of the adverse effects patients used to experience, such as leg pain and body aches.”